#South Korea #Seoul #SCLC #Risvutatug #ARTEMIS-008

Introduction

Recent findings from the Phase III ARTEMIS-008 trial have made waves in the oncological community by showcasing the impressive efficacy of risvutatug rezetecan (Ris-Rez) in treating relapsed small-cell lung cancer (SCLC). This trial highlights a significant breakthrough, providing hope for patients who have had limited treatment options after platinum-based chemotherapy.

Study Overview

Conducted across multiple centers in China, the Phase III ARTEMIS-008 trial was a randomized, open-label study involving 461 participants. Patients were assigned either to receive Ris-Rez at 8.0 mg/kg every three weeks or to undergo treatment with topotecan at 1.2 mg/m² administered from days one to five of a three-week cycle.

Notably, a substantial portion (over 80%) of these patients had previously been treated with PD-(L)1 inhibitors, adding an extra layer of complexity to their treatment journeys. The primary focus of the study was to evaluate overall survival, while secondary endpoints included progression-free survival, response rates, the disease control rate, and safety parameters.

Survival Rates Compared

As of the data cutoff on June 6, 2026, the median follow-up period was 12.2 months. The trial results showed a dramatic contrast in outcomes between the two treatment options: patients receiving Ris-Rez had a median overall survival of 18.5 months compared to just 10.3 months for those treated with topotecan. This translates to an impressive 54% reduction in death risk for patients on Ris-Rez (hazard ratio of 0.46; 95% CI, 0.35–0.62; p<0.0001).

The survival benefits associated with Ris-Rez remained consistent across various patient subgroups, underscoring the robustness of these results. Moreover, an independent blinded review affirmed these findings.

Progression-Free Survival and Response Rates

In addition to overall survival, other efficacy measures also favored Ris-Rez over topotecan. The median progression-free survival was recorded at 7.2 months for Ris-Rez compared to a mere 3.0 months for topotecan (hazard ratio of 0.33; 95% CI, 0.25–0.42). The objective response rate (the percentage of patients whose cancer shrinks or disappears after treatment) was significantly higher with Ris-Rez, recorded at 58.3% against 12.6% for topotecan. Furthermore, the disease control rate was also substantially better at 90.4% versus 60.2%.

Safety and Adverse Events

Safety profiles are just as crucial as efficacy when evaluating treatment methods. Notably, serious adverse events were less frequent in the Ris-Rez cohort, with 60.9% of patients experiencing grade 3 or higher treatment-related adverse events, in contrast to 78.2% in the topotecan group. Among the most commonly reported severe adverse events were various hematologic toxicities, including reductions in neutrophil count, white blood cell count, anemia, and lymphocyte count.

Conclusion and Future Implications

Professor Jie Wang, from the National Cancer Center in China, emphasized the significance of these findings, stating, "Ris-Rez demonstrated a statistically significant and clinically meaningful overall survival benefit over topotecan in patients with SCLC that progressed after platinum-based therapy, with a favorable safety profile."

These groundbreaking results raise the possibility of Ris-Rez establishing a new standard of care for patients with relapsed SCLC, a much-needed advancement in a field that often struggles with high mortality rates and limited treatment options. With further studies and evaluations, Ris-Rez could soon transform the landscape of SCLC treatment, offering new hope to those battling this challenging form of cancer.

For more information about the study and its implications, the IASLC continues to emphasize its commitment to enhancing knowledge and collaboration in the lung cancer community globally.